Oxford Biomedica Expands US Presence with North Carolina Viral Vector Facility Acquisition

Oxford Biomedica buys FDA‑approved US viral vector plant: what’s in the deal

Oxford Biomedica (OXB) has snapped up a commercial-scale, FDA approved viral vector manufacturing facility in Durham, North Carolina from Resilience. The move adds meaningful US Good Manufacturing Practice (GMP) capacity across both drug substance and fill-finish, aiming squarely at late-stage and commercial work, particularly in adeno-associated virus (AAV).

The price is $4.5 million (£3.4 million), funded from existing cash. Integration is underway, with key functions expected to be operational by Q1 2026. Guidance is unchanged: management still expects above-market growth and EBITDA profitability from FY 2025 on a constant currency basis.

Why this North Carolina site matters for OXB’s growth story

For a contract development and manufacturing organisation (CDMO), capacity in the right place can make or break growth. This facility sits in Research Triangle Park, a major US biopharma hub, and is already FDA approved. That matters for two reasons: it shortens the route to revenue (no build-from-scratch lag) and de-risks regulatory readiness for commercial programmes.

Strategically, it gives OXB the ability to support late-stage programmes and commercial launches from the US for global clients, with end-to-end services spanning drug substance to fill-finish. The company highlights AAV in particular, but the broader message is clear: multi-vector, multi-site capability with a proper US commercial foothold.

What exactly OXB is acquiring in Durham

• Two operational GMP drug substance suites.
• A dedicated GMP fill-finish suite.
• One additional GMP suite that is expansion-ready.
• On-site quality control (QC) labs and warehousing.

That combination means OXB can take client programmes further down the line in the US, not just develop processes. It complements Bedford, MA, which remains an AAV centre of excellence for process and analytical development, focusing on early-stage work. In short: develop in Bedford, scale and commercialise in Durham.

How it fits with OXB’s wider network and strategy

OXB has been open about its plan to build US commercial-scale GMP capacity. In August 2025, it raised approximately £60 million (gross) to strengthen its CDMO network, including US expansion and improving process quality, productivity and yields. Today’s acquisition is a straight execution step on that plan.

The new US site slots into a broader footprint across Oxford, Lyon, Strasbourg, Bedford (MA) and now Durham (NC). That unified network supports clients across lentivirus, AAV, adenovirus and other vector types from early-stage development through to commercialisation. The pitch to customers: more capacity, faster onboarding, and a credible US base for launches.

Numbers investors should note

Purchase price	$4.5 million (£3.4 million)
Funding	Existing cash
Operational status	FDA approved; integration in progress
Facilities	2 operational GMP drug substance suites; 1 dedicated fill-finish suite; 1 expansion-ready GMP suite; on-site QC labs and warehousing
Timeline	Key functions expected operational by Q1 2026
2025 P&L effect	Single-digit gain expected, broadly offsetting acquisition-related and operational costs
Guidance	Unchanged – above-market growth; EBITDA profitability from FY 2025 (constant currency)
Recent equity raise	c.£60 million (August 2025) to support network expansion

Financial impact: helpful, but not a near‑term needle-mover

OXB expects a single-digit gain in 2025 tied to the transaction, which should broadly offset acquisition and operating costs at the new site this year. In plain English: don’t expect a big profit swing right away. The value here is more about enabling growth in late-stage and commercial programmes from 2026 onwards.

Crucially, the company is reiterating guidance. Above-market growth and EBITDA profitability from FY 2025 (constant currency) remain the targets. That consistency suggests the deal slots neatly into existing plans rather than forcing a major reset.

Execution to watch: hiring, capex and client onboarding

OXB plans to invest in the facility, including hiring additional operational staff, boosting US fill-finish capacity and speeding up client onboarding. It also intends to continue strategic investments at existing sites, with capital expenditure expectations largely consistent with what was announced in August 2025.

The risk is straightforward CDMO execution: integrate the asset, staff it, qualify it to client standards, and convert pipeline into revenue. The upside is equally clear: commercial-ready US capacity in a hot geography, with the ability to win and retain larger, later-stage programmes.

Why this is positive for competitive positioning

Adding US commercial-scale capability should make OXB stickier with existing clients and more attractive to US biotechs and pharmas that prefer domestic manufacturing for launch. The inclusion of fill-finish is a big plus, reducing handoffs between suppliers and simplifying regulatory pathways for clients.

Combined with OXB’s technology stack – including its 4th generation lentiviral vector system and AAV production systems – the network now spans from early development to commercialisation across major vector types. That breadth is exactly what large clients look for in a long-term partner.

Balanced view: the good and the watch-outs

What’s encouraging

• Low headline consideration of $4.5 million (£3.4 million) for an FDA approved, commercial-ready site.
• Immediate expansion of US capabilities across drug substance and fill-finish, focused on late-stage and commercial work.
• Network logic is clear: Bedford for early-stage AAV development, Durham for clinical and commercial activities.
• Guidance held steady – no sign of near-term financial strain from the deal.

What to monitor

• Integration and staffing timelines – key functions targeted by Q1 2026.
• Actual client wins into the new capacity, especially AAV late-stage programmes.
• Capital needs to bring the site to full commercial readiness – plans are consistent with August guidance, but execution is key.
• Margin progression as utilisation ramps – single-digit 2025 gain suggests limited near-term P&L impact.

Jargon buster for quick clarity

• CDMO: Contract development and manufacturing organisation – a company that develops and makes drugs for clients.
• GMP: Good Manufacturing Practice – regulatory quality standards required for clinical and commercial manufacture.
• AAV: Adeno-associated virus – a viral vector commonly used to deliver gene therapies.
• Drug substance: The active viral vector material before it is filled into final containers.
• Fill-finish: The process of filling the drug into vials or syringes and finishing it for clinical or commercial use.
• QC labs: Quality control laboratories used to test and release materials and products.

Josh’s view: sensible capacity at a sensible price

This looks like a pragmatic, strategically tidy acquisition that strengthens OXB’s US footprint without stretching the balance sheet. The price is modest, the facility is FDA approved, and the location in Research Triangle Park is spot on for hiring and client proximity.

It will not transform 2025 numbers, and that is fine. The prize is in 2026 and beyond: faster onboarding, bigger late-stage mandates, and more seamless US commercial launches for clients. If OXB executes on hiring and utilisation, this should support the long-term growth and margin story that management has been signalling since the summer raise.